JP Morgan: Brandicourt Signals M&A Interest To Boost Sanofi's Growth

Olivier Brandicourt had a lot to say at his first JP Morgan as Sanofi CEO. With plans to deliver on an "underappreciated" vaccine portfolio, ambitions to "double revenues" from the multiple sclerosis franchise, and a "rebuilding" of the oncology pipeline through M&A, Scrip is enjoying Brandicourt's energy.